339 related articles for article (PubMed ID: 24341661)
1. Is lead chelation therapy effective for chronic kidney disease? A meta-analysis.
Yang SK; Xiao L; Song PA; Xu XX; Liu FY; Sun L
Nephrology (Carlton); 2014 Jan; 19(1):56-9. PubMed ID: 24341661
[TBL] [Abstract][Full Text] [Related]
2. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes.
Lin JL; Lin-Tan DT; Hsu KH; Yu CC
N Engl J Med; 2003 Jan; 348(4):277-86. PubMed ID: 12540640
[TBL] [Abstract][Full Text] [Related]
3. Effect of chelation therapy on progressive diabetic nephropathy in patients with type 2 diabetes and high-normal body lead burdens.
Chen KH; Lin JL; Lin-Tan DT; Hsu HH; Hsu CW; Hsu KH; Yen TH
Am J Kidney Dis; 2012 Oct; 60(4):530-8. PubMed ID: 22721929
[TBL] [Abstract][Full Text] [Related]
4. Lead mobilization during calcium disodium ethylenediaminetetraacetate chelation therapy in treatment of chronic lead poisoning.
Sánchez-Fructuoso AI; Cano M; Arroyo M; Fernández C; Prats D; Barrientos A
Am J Kidney Dis; 2002 Jul; 40(1):51-8. PubMed ID: 12087561
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases.
Lin-Tan DT; Lin JL; Yen TH; Chen KH; Huang YL
Nephrol Dial Transplant; 2007 Oct; 22(10):2924-31. PubMed ID: 17556414
[TBL] [Abstract][Full Text] [Related]
6. ["Terzo fuoco", lead poisoning and chronic renal failure].
Bonucchi D; Mondaini G; Ravera F; Minisci E; Albertazzi V; Arletti S; Mori G; Ballestri M; Piattoni J; Cappelli G
G Ital Nefrol; 2007; 24 Suppl 38():76-9. PubMed ID: 17922453
[TBL] [Abstract][Full Text] [Related]
7. Low-level environmental exposure to lead and progressive chronic kidney diseases.
Lin JL; Lin-Tan DT; Li YJ; Chen KH; Huang YL
Am J Med; 2006 Aug; 119(8):707.e1-9. PubMed ID: 16887418
[TBL] [Abstract][Full Text] [Related]
8. Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes.
Lin JL; Lin-Tan DT; Yu CC; Li YJ; Huang YY; Li KL
Kidney Int; 2006 Jun; 69(11):2049-56. PubMed ID: 16641918
[TBL] [Abstract][Full Text] [Related]
9. EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment.
Born T; Kontoghiorghe CN; Spyrou A; Kolnagou A; Kontoghiorghes GJ
Toxicol Mech Methods; 2013 Jan; 23(1):11-7. PubMed ID: 22991933
[TBL] [Abstract][Full Text] [Related]
10. Chronic industrial exposure to lead in 63 subjects. II. Evaluation of chelation therapy.
Strickland GT; Hwang YF; Chang NK; Blackwell RQ
Southeast Asian J Trop Med Public Health; 1976 Dec; 7(4):569-74. PubMed ID: 828980
[TBL] [Abstract][Full Text] [Related]
11. Experimental lead nephropathy: treatment with calcium disodium ethylenediaminetetraacetate.
Sánchez-Fructuoso AI; Blanco J; Cano M; Ortega L; Arroyo M; Fernández C; Prats D; Barrientos A
Am J Kidney Dis; 2002 Jul; 40(1):59-67. PubMed ID: 12087562
[TBL] [Abstract][Full Text] [Related]
12. Metal chelation therapy in rheumathoid arthritis: a case report. Successful management of rheumathoid arthritis by metal chelation therapy.
Bamonti F; Fulgenzi A; Novembrino C; Ferrero ME
Biometals; 2011 Dec; 24(6):1093-8. PubMed ID: 21655943
[TBL] [Abstract][Full Text] [Related]
13. Lead, zinc and copper decorporation during calcium disodium ethylenediamine tetraacetate treatment of lead-poisoned children.
Thomas DJ; Chisolm J
J Pharmacol Exp Ther; 1986 Dec; 239(3):829-35. PubMed ID: 3098962
[TBL] [Abstract][Full Text] [Related]
14. [Case of lead nephropathy due to chronic occupational lead exposure].
Ogata A; Sueta S; Tagawa M
Nihon Jinzo Gakkai Shi; 2011; 53(2):207-11. PubMed ID: 21516708
[TBL] [Abstract][Full Text] [Related]
15. Does calcium disodium EDTA slow CKD progression?
Weaver VM; Fadrowski JJ; Jaar BG
Am J Kidney Dis; 2012 Oct; 60(4):503-6. PubMed ID: 22985977
[No Abstract] [Full Text] [Related]
16. Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy.
Cory-Slechta DA; Weiss B; Cox C
J Pharmacol Exp Ther; 1987 Dec; 243(3):804-13. PubMed ID: 3121845
[TBL] [Abstract][Full Text] [Related]
17. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial.
Lin JL; Ho HH; Yu CC
Ann Intern Med; 1999 Jan; 130(1):7-13. PubMed ID: 9890856
[TBL] [Abstract][Full Text] [Related]
18. Combined chelation therapy in reducing tissue lead concentrations in suckling rats.
Kostial K; Blanusa M; Piasek M; Restek-Samarzija N; Jones MM; Singh PK
J Appl Toxicol; 1999; 19(3):143-7. PubMed ID: 10362263
[TBL] [Abstract][Full Text] [Related]
19. Detection and treatment of occupational lead nephropathy.
Wedeen RP; Malik DK; Batuman V
Arch Intern Med; 1979 Jan; 139(1):53-7. PubMed ID: 760684
[TBL] [Abstract][Full Text] [Related]
20. Reversible nephrotoxic reactions to a combined 2,3-dimercapto-1-propanol and calcium disodium ethylenediaminetetraacetic acid regimen in asymptomatic children with elevated blood lead levels.
Moel DI; Kumar K
Pediatrics; 1982 Aug; 70(2):259-62. PubMed ID: 7099793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
